| 000 | 00000nam 2200000za 4500 |
| 001 | 9.833914 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107150323 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 170327s2016 oncd os f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 041 | 0 |aeng|afre |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH82-23/2016-PDF |
|---|
| 245 | 04|aThe use of diabetes drugs in Canadian drug plans |h[electronic resource] = |bUtilisation des médicaments contre le dibète dans les régimes publics d'assurance-médicaments du Canada. |
|---|
| 246 | 31|aUtilisation des médicaments contre le dibète dans les régimes publics d'assurance-médicaments du Canada |
|---|
| 260 | |a[Ottawa] : |bPatented Medicine Prices Review Board, |c[2016] |
|---|
| 300 | |a[1] p. : |bcol. charts |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |aAt head of title: National Prescription Drug Utilization Information System. |
|---|
| 520 | |a"The cost of diabetes treatment has been rapidly increasing in Canada in recent years. While the growing prevalence of the disease is a contributing factor, more expensive treatments have been a major cost driver, especially given the uptake in new, higher-cost drugs. This study analyzes these issues from the perspective of Canadian public drug plans, and provides insight into the actual use of the newer and higher-cost diabetes drugs and their associated cost pressures. Results are presented for all public drug plans participating in NPDUIS: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and Health Canada’s Non-Insured Health Benefits drug plan. This analysis will support policy decision makers and the health technology assessment community in determining the future impact of diabetes treatments on their plans." |
|---|
| 546 | |aText in English and French. |
|---|
| 692 | 07|2gccst|aDiabetes |
|---|
| 692 | 07|2gccst|aDrug insurance |
|---|
| 692 | 07|2gccst|aPrescription drugs |
|---|
| 692 | 07|2gccst|aPrices |
|---|
| 710 | 1 |aCanada. |bPatented Medicine Prices Review Board. |
|---|
| 710 | 2 |aNational Prescription Drug Utilization Information System (Canada) |
|---|
| 792 | |tThe use of diabetes drugs in Canadian public drug plans |efre|w(CaOODSP)9.833915 |
|---|
| 856 | 40|qPDF|s351 KB|uhttps://publications.gc.ca/collections/collection_2017/cepmb-pmprb/H82-23-2016.pdf |
|---|